eligibility_summary
Adults ≥18 with untreated indolent B‑cell NHL (FL grade 1–3A or MZL), stage II–IV, low tumor burden by GELF, measurable disease, ECOG 0–2, adequate renal/hepatic function. Negative pregnancy test/contraception required. Exclude: severe mAb allergy, uncontrolled infections, HIV unless suppressed, HBV surface‑Ag+, active autoimmune therapy, HLH/MAS, major cardiac/pulmonary disease, steroids >10 mg/d, mAb <4 wks, organ transplant, concerning 2nd cancer, pregnant/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial testing low-dose mosunetuzumab (Lunsumio, RO7030816), a full-length bispecific monoclonal antibody (immunotherapy) that binds CD20 on B cells and CD3 on T cells, redirecting autologous T-cell cytotoxicity to kill malignant B cells. Mechanism: T-cell engagement via CD3/TCR signaling, immune synapse formation, cytokine release, and perforin/granzyme-mediated apoptosis of CD20+ lymphoma cells. Dosing: IV on days 1, 8, 15, 22. Targets: CD20+ indolent B-cell lymphomas (follicular grade 1–3A, marginal zone) and CD3+ T cells as effectors. Pathways: CD20 antigen on B cells, T-cell activation/cytotoxic pathways. Imaging (PET/CT, CT, MRI) and biospecimen collection are ancillary. Primary focus: safety, tolerability, and efficacy in treatment-naïve, low–tumor-burden stage II–IV disease.